Serum Vascular Endothelial Growth Factor C as a Marker of Therapeutic Response to Sirolimus in Lymphangioleiomyomatosis

Ann Am Thorac Soc. 2021 Jan;18(1):174-177. doi: 10.1513/AnnalsATS.202006-702RL.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Forced Expiratory Volume
  • Humans
  • Lymphangioleiomyomatosis* / blood
  • Lymphangioleiomyomatosis* / drug therapy
  • Sirolimus*
  • Vascular Endothelial Growth Factor C* / blood

Substances

  • VEGFC protein, human
  • Vascular Endothelial Growth Factor C
  • Sirolimus